The impact of the nocebo effect on discontinuation of statin therapy due to myopathy in patients with cardiovascular disease – a review
DOI:
https://doi.org/10.12775/QS.2024.31.55769Keywords
statins, nocebo effect, myopathy, cardiovascular diseases, dyslipidemia, hypercholesterolemia, literature review, drug discontinuationAbstract
Introduction and purpose of review: Statins are widely used drugs in the prevention of cardiovascular diseases, yet many patients experience side effects of statin use, mainly muscle symptoms, such as myopathy, which often lead to discontinuation of treatment. The aim of this literature review is to assess the role of the nocebo effect in reported muscle symptoms and its impact on statin discontinuation in patients with cardiovascular diseases.
Methods: The review analysed the results of several studies, including key publications such as the N-of-1 trial by Wood et al.[1] and the work of Collins et al.[2] on the safety and efficacy of statin therapy. The review covered articles published between 2000 and 2023 that examined the impact of the nocebo effect on statin discontinuation[3-10].
Results: The collected data indicate that the nocebo effect plays a significant role in the reported muscle symptoms during statin use. The study by Wood et al.[1] showed no significant differences in reported symptoms between the groups taking statins, placebo, or receiving no treatment, suggesting that a substantial portion of the symptoms results from the nocebo effect. Similar findings were obtained in the study conducted by the StatinWISE group[4], where patients taking statins and placebo reported a comparable frequency of muscle symptoms. An analysis conducted by Collins et al.[2] indicates that the actual incidence of myopathy associated with statin therapy is much lower than commonly reported.
Conclusions: The nocebo effect significantly influences the perceived adverse effects of statins, which may lead to the unjustified discontinuation of these drugs by patients with cardiovascular diseases. Further research is needed to better understand the psychological mechanisms affecting statin tolerance and to develop educational and clinical strategies aimed at minimizing the nocebo effect and improving long-term adherence to therapy.
References
Wood FA, Howard JP, Finegold JA, et al. "N-of-1 trial of a statin, placebo, or no treatment to assess side effects." New England Journal of Medicine. 2020; 383:2182-2184.
Collins R, Armitage J, Parish S, et al. "Interpretation of the evidence for the efficacy and safety of statin therapy." Lancet. 2016; 388(10059):2532-2561.
Gupta A, Thompson D, Whitehouse A, et al.ASCOT Investigators . Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017;389:2473-81. 10.1016/S0140-6736(17)31075-9
Herrett E, Williamson E, Brack K, et al. "Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials." BMJ. 2021; 372.
Finegold JA, Manisty CH, Goldacre B, et al. "What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug?" European Journal of Preventive Cardiology. 2014; 21(4):464-474.
Thavendiranathan P, Bagai A, Brookhart MA, et al. "Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials." Archives of Internal Medicine. 2006; 166(21):2307-2313.
Kashani A, Phillips CO, Foody JM, et al. "Risks associated with statin therapy: A systematic overview of randomized clinical trials." Circulation. 2006; 114(25):2788-2797.
Taylor F, Huffman MD, Macedo AF, et al. "Statins for the primary prevention of cardiovascular disease." Cochrane Database of Systematic Reviews. 2013; (1).
Zhang H, Plutzky J, Skentzos S, et al. "Discontinuation of statins in routine care settings: A cohort study." Annals of Internal Medicine. 2013; 158(7):526-534.
Stroes ES, Thompson PD, Corsini A, et al. "Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel statement on assessment, aetiology, and management." European Heart Journal. 2015; 36(17):1012-1022.
Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015 Mar 26;161(1):161-172. doi: 10.1016/j.cell.2015.01.036. PMID: 25815993; PMCID: PMC4525717.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144. PMID: 28444290; PMCID: PMC5837225.
Banach M., Michailidis DP. Nietolerancja statyn: kilka praktycznych wskazówek . Cardiol Clin 2018; 36 :225–231 -LINK
Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. Int J Cardiol. 2016 Dec 15;225:184-196. doi: 10.1016/j.ijcard.2016.09.075.
Penson PE, Bruckert E, Marais D, Reiner Ž, Pirro M, Sahebkar A, Bajraktari G, Mirrakhimov E, Rizzo M, Mikhailidis DP, Sachinidis A, Gaita D, Latkovskis G, Mazidi M, Toth PP, Pella D, Alnouri F, Postadzhiyan A, Yeh HI, Mancini GBJ, von Haehling S, Banach M; International Lipid Expert Panel (ILEP). Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1596-1622. doi: 10.1002/jcsm.12960
Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, Gąsior M, Jankowski P, Jóźwiak J, Kłosiewicz-Latoszek L, Kowalska I, Małecki M, Prejbisz A, Rakowski M, Rysz J, Solnica B, Sitkiewicz D, Sygitowicz G, Sypniewska G, Tomasik T, Windak A, Zozulińska-Ziółkiewicz D, Cybulska B. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021 Nov 8;17(6):1447-1547. doi: 10.5114/aoms/141941.
Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016 Jul-Aug;10(4):739-747. doi: 10.1016/j.jacl.2016.05.002. Epub 2016 May 13. PMID: 27578103.
Malcolm Law, Alicja R. Rudnicka. Statin Safety: A Systematic Review. Am J Cardiol. 2006; 97: 52C-60C.
Naci H, Brugts J, Ades T. Comparative tolerability and harms of individu - al statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013; 6: 390–399.
Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014 Nov-Dec;8(6):554-561. doi: 10.1016/j.jacl.2014.09.007. Epub 2014 Sep 19. PMID: 25499937.
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608. PMID: 27039291.
Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014;12:51. 10.1186/1741-7015-12-51
Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7. 10.1001/jama.287.5.622
Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med 2017;167:221-7. 10.7326/M16-0838
Mampuya WM, Frid D, Rocco M, et al.. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013;166:597-603. 10.1016/j.ahj.2013.06.004
Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ 2013; 347: f6123.
Armitage J. The safety of statins in clinical practice. Lancet. 2007 Nov 24;370(9601):1781-90. doi: 10.1016/S0140-6736(07)60716-8. PMID: 17559928.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. PMID: 18997196
Blom J, den Elzen W, van Houwelingen AH, Heijmans M, Stijnen T, Van den Hout W, Gussekloo J. Effectiveness and cost-effectiveness of a proactive, goal-oriented, integrated care model in general practice for older people. A cluster randomised controlled trial: Integrated Systematic Care for older People--the ISCOPE study. Age Ageing. 2016 Jan;45(1):30-41. doi: 10.1093/ageing/afv174. PMID: 26764392; PMCID: PMC4711660.
van der Ploeg MA, Poortvliet RK, van Blijswijk SC, den Elzen WP, van Peet PG, de Ruijter W, Blom JW, Gussekloo J. Statin Use and Self-Reported Hindering Muscle Complaints in Older Persons: A Population Based Study. PLoS One. 2016 Dec 2;11(12):e0166857. doi: 10.1371/journal.pone.0166857. Erratum in: PLoS One. 2021 Jan 22;16(1):e0245997. doi: 10.1371/journal.pone.0245997. PMID: 27911918; PMCID: PMC5135075.
van Blijswijk SC, Chan OY, van Houwelingen AH, Gussekloo J, den Elzen WP, Blom JW. Self-Reported Hindering Health Complaints of Community-Dwelling Older Persons: A Cross-Sectional Study. PLoS One. 2015 Nov 16;10(11):e0142416. doi: 10.1371/journal.pone.0142416. PMID: 26571233; PMCID: PMC4646486.
Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14. doi: 10.1007/s10557-005-5686-z. PMID: 16453090.
Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012 Feb 8;307(6):567-8. doi: 10.1001/jama.2012.115. PMID: 22318275; PMCID: PMC6909539.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):871-5. doi: 10.1016/j.numecd.2012.04.012. Epub 2012 Jun 29. PMID: 22748604.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9. PMID: 7968073.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 Nov 5;339(19):1349-57. doi: 10.1056/NEJM199811053391902. PMID: 9841303.
Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997 Jan 16;336(3):153-62. doi: 10.1056/NEJM199701163360301. Erratum in: N Engl J Med 1997 Dec 18;337(25):1859. PMID: 8992351
Cai T, Abel L, Langford O, Monaghan G, Aronson JK, Stevens RJ, Lay-Flurrie S, Koshiaris C, McManus RJ, Hobbs FDR, Sheppard JP. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021 Jul 14;374:n1537. doi: 10.1136/bmj.n1537. PMID: 34261627; PMCID: PMC8279037.
Ramkumar S, Raghunath A, Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016 Nov;32(6):631-639. doi: 10.6515/acs20160611a. PMID: 27899849; PMCID: PMC5126440.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jakub Stanek, Patrycja Sornek, Wiktoria Izdebska, Agata Borkowska, Radosław Ciesielski, Anna Kaźmierczak, Anna Kiełb, Anna Mich, Klaudia Perkowska, Igor Pawlak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 53
Number of citations: 0
